
Antiverse Raises $9.3M for AI Antibody Scaling
Cardiff-based biotech Antiverse raised $9.3M in Series A funding to expand its AI-powered platform for therapeutic antibody discovery. Led by Soulmates Ventures, the round includes Innovation Investment Capital, DOMiNO Ventures, and existing investors. Funds will advance lead programs to in vivo studies.






